Skip to main content

Advertisement

Log in

Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Patients with superficial vein thrombosis (SVT) are commonly treated with low-molecular weight heparin or fondaparinux in prophylactic, intermediate or therapeutic dosages for treatment periods of 10–45 days. This practice is also reflected by the current guideline recommendations. However, given the broad range of thromboembolic complication rates in SVT (between 0 and 30 % have been reported) it seems reasonable to suspect that risk stratification is needed to differentiate patients at low risk who may not benefit from anticoagulation from those at high risk who may need higher dosages or a longer duration of anticoagulation. Furthermore, prolonged treatment with injectable anticoagulants has been shown to result in poor patient adherence. Direct oral anticoagulants have recently been approved for venous thromboembolism therapy and these new drugs may offer advantages also for SVT patients. The prospective, randomized, open-label, blinded adjudication trial superficial phlebitis treated for 45 days with rivaroxaban versus fondaparinux (SURPRISE) will evaluate the efficacy and safety of 10 mg rivaroxaban OD compared to fondaparinux 2.5 mg OD for SVT treatment in a subset of high-risk SVT patients over a treatment period of 45 days. The purpose of the study is to demonstrate non-inferiority of rivaroxaban compared to fondaparinux in preventing the combined efficacy endpoint of thrombus progression, SVT recurrence, DVT, PE and death. The results of the SURPRISE trial will provide evidence for the concept of risk stratification in SVT and for the value of rivaroxaban 10 mg in SVT treatment (clinicaltrials.gov NCT01499953).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Coon WW, Willis PW 3rd, Keller JB (1973) Venous thromboembolism and other venous disease in the Tecumseh community health study. Circulation 48(4):839–846

    Article  CAS  PubMed  Google Scholar 

  2. Frappe P, Buchmuller-Cordier A, Bertoletti L, Bonithon-Kopp C, Couzan S, Lafond P, Leizorovicz A, Merah A, Presles E, Preynat P, Tardy B, Decousus H (2014) Annual diagnosis rate of superficial vein thrombosis of the lower limbs: the STEPH community-based study. J Thromb Haemost 12(6):831–838

    Article  CAS  PubMed  Google Scholar 

  3. Decousus H, Quere I, Presles E, Becker F, Barrellier MT, Chanut M, Gillet JL, Guenneguez H, Leandri C, Mismetti P, Pichot O, Leizorovicz A (2010) Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann Intern Med 152(4):218–224

    Article  PubMed  Google Scholar 

  4. Karathanos C, Exarchou M, Tsezou A, Kyriakou D, Wittens C, Giannoukas A (2013) Factors associated with the development of superficial vein thrombosis in patients with varicose veins. Thromb Res 132(1):47–50

    Article  CAS  PubMed  Google Scholar 

  5. Decousus H, Bertoletti L, Frappe P (2015) Spontaneous acute superficial vein thrombosis of the legs: do we really need to treat? J Thromb Haemost 13(Suppl 1):S230–S237

    Article  PubMed  Google Scholar 

  6. Galanaud JP, Genty C, Sevestre MA, Brisot D, Lausecker M, Gillet JL, Rolland C, Righini M, Leftheriotis G, Bosson JL, Quere I (2011) Predictive factors for concurrent deep-vein thrombosis and symptomatic venous thromboembolic recurrence in case of superficial venous thrombosis. The OPTIMEV study. Thromb Haemost 105(1):31–39

    Article  CAS  PubMed  Google Scholar 

  7. Decousus H, Prandoni P, Mismetti P, Bauersachs RM, Boda Z, Brenner B, Laporte S, Matyas L, Middeldorp S, Sokurenko G, Leizorovicz A (2010) Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med 363(13):1222–1232

    Article  CAS  PubMed  Google Scholar 

  8. STENOX study group (2003) A pilot randomized double-blind comparison of a low-molecular-weight heparin, a nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Arch Intern Med 163(14):1657–1663

    Article  Google Scholar 

  9. Prandoni P, Tormene D, Pesavento R (2005) High vs. low doses of low-molecular-weight heparin for the treatment of superficial vein thrombosis of the legs: a double-blind, randomized trial. J Thromb Haemost 3(6):1152–1157

    Article  CAS  PubMed  Google Scholar 

  10. Cosmi B, Filippini M, Tonti D, Avruscio G, Ghirarduzzi A, Bucherini E, Camporese G, Imberti D, Palareti G (2012) A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). J Thromb Haemost 10(6):1026–1035

    Article  CAS  PubMed  Google Scholar 

  11. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e419S–e494S

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Blondon M, Righini M, Bounameaux H, Veenstra DL (2011) Fondaparinux for isolated superficial-vein thrombosis of the legs: a cost-effectiveness analysis. Chest 141(2):321–329

    Article  PubMed  Google Scholar 

  13. Wilke T, Moock J, Muller S, Pfannkuche M, Kurth A (2010) Nonadherence in outpatient thrombosis prophylaxis with low molecular weight heparins after major orthopaedic surgery. Clin Orthop Relat Res 468(9):2437–2453

    Article  PubMed  PubMed Central  Google Scholar 

  14. Quenet S, Laporte S, Decousus H, Leizorovicz A, Epinat M, Mismetti P (2003) Factors predictive of venous thrombotic complications in patients with isolated superficial vein thrombosis. J Vasc Surg 38(5):944–949

    Article  PubMed  Google Scholar 

  15. Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692–694

    Article  CAS  PubMed  Google Scholar 

  16. Einstein-Investigators Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499–2510. doi:10.1056/NEJMoa1007903

    Article  Google Scholar 

  17. Einstein-PE-Investigators Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366(14):1287–1297. doi:10.1056/NEJMoa1113572

    Article  Google Scholar 

Download references

Authors’ contribution

JBW wrote the first draft of the trial protocol and is the lead investigator of SURPRISE. SW wrote the first draft of this manuscript. RB, HG, ER, SMSS and JBW represent the Steering Committee of SURPRISE and contributed to the design and oversight of the study. All authors contributed to the preparation of this manuscript and approved the final version.

Funding

This investigator-initiated trial is sponsored by funding of the Bayer Vital GmbH. The company also provides the investigational product.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jan Beyer-Westendorf.

Ethics declarations

Conflict of interest

SW has received research support and honoraria for lectures and advisory boards from Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, LeoPharma and Pfizer. RB has received research support and honoraria for lectures and advisory boards from Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb, Boehringer and Daiichi Sankyo, and ASPEN. HG has received honoraria for lectures and advisory boards from Aspen, Bayer, Boehringer-Ingelheim and LeoPharma. ER has received honoraria for lectures and advisory boards from Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, LeoPharma and Pfizer. SMS has received honoraria for lectures and advisory boards from Bayer, Pfizer, Boehringer-Ingelheim, Daiichi-Sankyo and LeoPharma. JBW has received research support and honoraria for lectures and advisory boards from Bayer, Pfizer, Boehringer-Ingelheim, Daiichi-Sankyo and LeoPharma.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Werth, S., Bauersachs, R., Gerlach, H. et al. Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial. J Thromb Thrombolysis 42, 197–204 (2016). https://doi.org/10.1007/s11239-016-1354-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-016-1354-3

Keywords

Navigation